Print Page     Close Window     

Press Releases

Selecta Biosciences Announces Addition of Patrick J. Zenner to Board of Directors

WATERTOWN, Mass., June 19, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced the election of Patrick J. Zenner to its Board of Directors at the company’s 2017 Annual Meeting of Stockholders, which was held on June 16, 2017. Mr. Zenner previously served as President and Chief Executive Officer of Hoffmann-La Roche Inc., North America, the prescription drug unit of Roche.

“I am delighted that we were able to add an executive of Patrick’s caliber to Selecta’s Board of Directors,” said Werner Cautreels, Ph.D., CEO and Chairman of Selecta. “We believe his experience in leading an expanding organization, navigating regulatory hurdles and commercializing a range of major therapeutics will be key as we seek to advance our clinical programs and enable new treatments using our Synthetic Vaccine Particles (SVP™) technology platform.”

Prior to his retirement, Mr. Zenner held various positions during his 32-year career at Roche. He currently serves as chairman of the boards of directors of both ArQule, Inc. and West Pharmaceutical Services, Inc. Previously, Mr. Zenner served as a director of Par Pharmaceuticals and several other public and private company boards. He received his B.S.B.A. from Creighton University and his M.B.A. from Fairleigh Dickinson University.

About Selecta Biosciences, Inc.
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options. The company’s current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company’s lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta’s clinical oncology candidate, LMB-100, is in a Phase 1 program targeting pancreatic cancer and mesothelioma. Its two proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP is also being explored in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com and follow @SelectaBio on Twitter.

Forward-Looking Statements
Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the company”), including without limitation, the company’s ability to unlock the full potential of biologic therapies, the company’s plan to apply its SVP platform to a range of biologics for rare and serious diseases, the potential of SEL-212 to treat severe gout patients and resolve their debilitating symptoms, the potential of the company’s two gene therapy product candidates to enable repeat administration, the potential treatment applications for products utilizing the SVP platform in areas such as gene therapy, immuno-oncology, allergies, autoimmune diseases and vaccines, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors discussed in the “Risk Factors” section of the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on May 11, 2017, and in other filings that the company makes with the SEC. In addition, any forward-looking statements included in this press release represent the company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The company specifically disclaims any obligation to update any forward-looking statements included in this press release.

Contact Information:

Jason Fredette
Selecta Biosciences, Inc.
617-231-8078
jfredette@selectabio.com

Primary Logo

Selecta Biosciences

© Selecta Biosciences, Inc. All rights reserved.